Shield Bio

Shield Bio was a precision medicine company developing a proprietary platform designed for rapid and reliable nanopore sequencing within clinical environments. Their core focus was on integrating third-generation, or "nanopore," sequencing technology into clinical practice to advance the field of precision medicine. Initially, Shield Bio aimed to leverage this technology to enhance the treatment of infectious diseases, specifically addressing the significant clinical challenge of sepsis, a condition responsible for approximately 300,000 deaths annually in the United States alone. The company is now inactive.